Literature DB >> 20541313

Homogeneous prostate cancer mortality in the Nordic countries over four decades.

Mara S Meyer1, Lorelei A Mucci, Swen-Olof Andersson, Ove Andrén, Jan-Erik Johansson, Steinar Tretli, Hans-Olov Adami.   

Abstract

BACKGROUND: Incidence of prostate cancer (PCa) has greatly increased in the Nordic region over the past two decades, following the advent of prostate-specific antigen (PSA) screening. Consequently, interpreting temporal trends in PCa has become difficult, and the impact of changes in exposure to causal factors is uncertain.
OBJECTIVE: To reveal geographic differences and temporal trends in PCa in the Nordic countries. Because the recorded incidence of PCa has been profoundly influenced by PSA screening, we focused our analyses primarily on PCa mortality. DESIGN, SETTING, AND PARTICIPANTS: We analyzed national PCa incidence and mortality data from Denmark, Finland, Norway, and Sweden from 1965 to 2006 using the PC-NORDCAN software program and the online NORDCAN database. MEASUREMENTS: Cumulative incidence and cumulative mortality from PCa were calculated for selected calendar years during four decades, along with age-standardized mortality rates. Incidence data in NORDCAN come from individual countries' cancer registries, and mortality data come from national mortality registries. RESULTS AND LIMITATIONS: From 1965 to 2006, 172 613 deaths from PCa were reported in the four Nordic countries. A substantial rise in incidence was observed across the region, with some geographic variation, since the late 1980s. In contrast, both disease-specific mortality rates and cumulative risk of PCa mortality lacked consistent temporal trends over the same period. Cumulative mortality from PCa ranged between 3.5% and 7.5% in the region over four decades, whereas cumulative incidence jumped from about 9% to >20%. Mortality has remained fairly constant among the countries, with a minimally lower risk in Finland.
CONCLUSIONS: Unlike most malignancies, the occurrence of lethal PCa showed minimal geographic variation and lacked consistent temporal trends over four decades. These findings may guide our search for important causes of PCa, a malignancy with etiology that is still largely unknown. (c) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541313      PMCID: PMC2936655          DOI: 10.1016/j.eururo.2010.05.040

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  Smoking and fatal prostate cancer in a large cohort of adult men.

Authors:  C Rodriguez; L M Tatham; M J Thun; E E Calle; C W Heath
Journal:  Am J Epidemiol       Date:  1997-03-01       Impact factor: 4.897

3.  Trends in smoking prevalence in Danish adults, 1964-1994. The influence of gender, age, and education.

Authors:  M Osler; E Prescott; A Gottschau; A Bjerg; H O Hein; A Sjøl; P Schnohr
Journal:  Scand J Soc Med       Date:  1998-12

Review 4.  Ethics of a prostate cancer screening trial.

Authors:  H O Adami; J A Baron; K J Rothman
Journal:  Lancet       Date:  1994-04-16       Impact factor: 79.321

5.  The prostate cancer pseudo-epidemic.

Authors:  Hans-Olov Adami
Journal:  Acta Oncol       Date:  2010-04       Impact factor: 4.089

6.  Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors.

Authors:  F Helgesen; L Holmberg; J E Johansson; R Bergström; H O Adami
Journal:  J Natl Cancer Inst       Date:  1996-09-04       Impact factor: 13.506

7.  Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.

Authors:  Rune Kvåle; Anssi Auvinen; Hans-Olov Adami; Asa Klint; Eivor Hernes; Bjørn Møller; Eero Pukkala; Hans H Storm; Laufey Tryggvadottir; Steinar Tretli; Rolf Wahlqvist; Elisabete Weiderpass; Freddie Bray
Journal:  J Natl Cancer Inst       Date:  2007-12-11       Impact factor: 13.506

8.  Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.

Authors:  Simon M Collin; Richard M Martin; Chris Metcalfe; David Gunnell; Peter C Albertsen; David Neal; Freddie Hamdy; Peter Stephens; J Athene Lane; Rollo Moore; Jenny Donovan
Journal:  Lancet Oncol       Date:  2008-04-16       Impact factor: 41.316

9.  Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

Authors:  Jing Ma; Haojie Li; Ed Giovannucci; Lorelei Mucci; Weiliang Qiu; Paul L Nguyen; J Michael Gaziano; Michael Pollak; Meir J Stampfer
Journal:  Lancet Oncol       Date:  2008-10-03       Impact factor: 41.316

10.  Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.

Authors:  Jan Adolfsson; Hans Garmo; Eberhard Varenhorst; Göran Ahlgren; Christer Ahlstrand; Ove Andrén; Anna Bill-Axelson; Ola Bratt; Jan-Erik Damber; Karin Hellström; Magnus Hellström; Erik Holmberg; Lars Holmberg; Jonas Hugosson; Jan-Erik Johansson; Bill Petterson; Magnus Törnblom; Anders Widmark; Pär Stattin
Journal:  Scand J Urol Nephrol       Date:  2007
View more
  3 in total

1.  The heritability of prostate cancer in the Nordic Twin Study of Cancer.

Authors:  Jacob B Hjelmborg; Thomas Scheike; Klaus Holst; Axel Skytthe; Kathryn L Penney; Rebecca E Graff; Eero Pukkala; Kaare Christensen; Hans-Olov Adami; Niels V Holm; Elizabeth Nuttall; Steinbjorn Hansen; Mikael Hartman; Kamila Czene; Jennifer R Harris; Jaakko Kaprio; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-08       Impact factor: 4.254

2.  Temporal trends in cause of death among Swedish and US men with prostate cancer.

Authors:  Mara M Epstein; Gustaf Edgren; Jennifer R Rider; Lorelei A Mucci; Hans-Olov Adami
Journal:  J Natl Cancer Inst       Date:  2012-07-25       Impact factor: 13.506

Review 3.  Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

Authors:  Lisa M Lowenstein; Spyridon P Basourakos; Michelle D Williams; Patricia Troncoso; Justin R Gregg; Timothy C Thompson; Jeri Kim
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.